<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03634969</url>
  </required_header>
  <id_info>
    <org_study_id>CV016-010</org_study_id>
    <nct_id>NCT03634969</nct_id>
  </id_info>
  <brief_title>An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants</brief_title>
  <official_title>A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of BMS-986224 in Participants With Varying Degrees of Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the experimental medication BMS-986224 in
      participants with varying levels of renal function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 14, 2018</start_date>
  <completion_date type="Actual">April 30, 2019</completion_date>
  <primary_completion_date type="Actual">April 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of BMS-986224</measure>
    <time_frame>Up to 11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)] of BMS-986224</measure>
    <time_frame>Up to 11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to 72 h post dose [AUC(0-72)] of BMS-986224</measure>
    <time_frame>Up to 11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-986224</measure>
    <time_frame>Up to 11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of BMS-986224</measure>
    <time_frame>Up to 11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination half-life (T-HALF) of BMS-986224 derived from plasma concentration</measure>
    <time_frame>Up to 11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fraction of unbound drug in plasma (fu) of BMS-986224</measure>
    <time_frame>Up to 11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent oral clearance (CL/F) of BMS-986224 derived from plasma concentration</measure>
    <time_frame>Up to 11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution (Vz/F) of BMS-986224 derived from plasma concentration</measure>
    <time_frame>Up to 11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative amount of unchanged drug excreted into the urine at a given time (Aet) of BMS-986224</measure>
    <time_frame>7 days</time_frame>
    <description>Part 1 only</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fraction of dose excreted in urine (Fe%) of BMS-986224</measure>
    <time_frame>7 days</time_frame>
    <description>Part 1 only</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal clearance of BMS-986224 derived from urine concentration</measure>
    <time_frame>7 days</time_frame>
    <description>Part 1 only</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of nonserious adverse events (AE), serious adverse events (SAE), and AE leading to discontinuation</measure>
    <time_frame>Up to 41 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of metabolite</measure>
    <time_frame>Up to 11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)] of metabolite</measure>
    <time_frame>Up to 11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to 72 h post dose [AUC(0-72)] of metabolite</measure>
    <time_frame>Up to 11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of metabolite</measure>
    <time_frame>Up to 11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of metabolite</measure>
    <time_frame>Up to 11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (T-HALF) of metabolite derived from plasma concentration</measure>
    <time_frame>Up to 11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolite-to-parent (MR) ratio for cMax</measure>
    <time_frame>Up to 11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolite-to-parent (MR) ratio for AUC(0-T)</measure>
    <time_frame>Up to 11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolite-to-parent (MR) ratio for AUC(0-72)</measure>
    <time_frame>Up to 11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolite-to-parent (MR) ratio for AUC(INF)</measure>
    <time_frame>Up to 11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of clinically significant changes in vital signs, ECGs, physical examinations, or clinical laboratory tests</measure>
    <time_frame>Up to 11 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Cardiac Failure</condition>
  <condition>Myocardial Failure</condition>
  <arm_group>
    <arm_group_label>Normal Renal Function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>End-Stage Renal Disease (ESRD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ESRD participants and are on chronic hemodialysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986224</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>End-Stage Renal Disease (ESRD)</arm_group_label>
    <arm_group_label>Mild Renal Impairment</arm_group_label>
    <arm_group_label>Moderate Renal Impairment</arm_group_label>
    <arm_group_label>Normal Renal Function</arm_group_label>
    <arm_group_label>Severe Renal Impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  BMI ≥18 and ≤ 35kg/m2

          -  Systolic blood pressure &gt;100 mmHg

        Exclusion Criteria:

          -  Women of childbearing potential or women who are currently pregnant

          -  Clinically relevant abnormal medical history, abnormal findings on physical
             examination, vital signs, ECG, or laboratory tests at screening that the investigator
             judges as likely to interfere with the objectives of the trial or the safety of the
             volunteer

          -  Current or recent (within 3 months of study treatment administration) gastrointestinal
             disease that could affect absorption

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prism Research</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 15, 2018</study_first_submitted>
  <study_first_submitted_qc>August 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

